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Fanconi anemia (FA) is an autosomal recessive chromosomal instability syndrome with at least seven different
complementation groups. Four FA genes (FANCA, FANCC, FANCF, and FANCG) have been identified, and two
other FA genes (FANCD and FANCE) have been mapped. Here we report the identification, by complementation
cloning, of the gene mutated in FA complementation group E (FANCE). FANCE has 10 exons and encodes a novel
536–amino acid protein with two potential nuclear localization signals.
Fanconi anemia (FA) is characterized by bone marrow
failure, developmental abnormalities, cancer predisposi-
tion, and cellular hypersensitivity to DNA cross-linking
agents such as mitomycin C (Auerbach et al. 1998 [MIM
227650]). Complementation analysis has indicated that
mutations in at least seven different genes can cause FA
(Joenje et al. 1997, 2000). Four FA genes have been iden-
tified: FANCA (Fanconi Anemia/Breast Cancer Consor-
tium 1996; Lo ten Foe et al. 1996 [MIM 227650]),
FANCC (Strathdee et al. 1992 [MIM 227645]), FANCF
(de Winter et al. 2000 [MIM 603467]) and FANCG (de
Winter et al. 1998 [MIM 602956]). Intriguingly, none of
these genes has revealed any decisive clue toward a mo-
lecular function of the FA pathway, since they encode
novel proteins that lack significant functional domains.
The recently described homology between FANCF and
the RNA-binding protein ROM (de Winter et al. 2000)
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appeared to be nonsignificant, because mutations in the
FANCF region homologous to ROM did not affect the
function of FANCF (J. P. de Winter, unpublished data).
Two other FA genes, FANCD and FANCE, have been
mapped to chromosomes 3p25.3 (Whitney et al. 1995;
Hejna et al. 2000 [MIM 227646]) and 6p21-22 (Waisfisz
et al. 1999 [MIM 600901]), respectively.
Here we report the cloning of a cDNA representing
FANCE, by complementation of the FA-E lymphoblastoid
cell line EUFA410 (Waisfisz et al. 1999) with an episomal
expression library (Strathdee et al. 1992). After selection
for library uptake in hygromycin-containing medium
(100 mg/ml) and subsequent selection for resistance to
mitomycin C (15 nM), 4 of the 12 cDNA clones that we
recovered from the pool of complemented cells had iden-
tical inserts of ∼2.5 kb. Secondary transfection of one of
these cDNA clones (clone 10 [GenBank accession number
AF265210]) into EUFA410 cells again complemented
theirMMC-hypersensitive phenotype (fig. 1a). The cDNA
insert has a 1,611-nucleotide open reading frame encod-
ing a 536–amino acid protein (fig. 1b). The predicted
FANCE protein contains two potential nuclear localiza-
tion signals but, like the other FA proteins, lacks any
significant homology to other proteins.
The Stanford high-resolution TNG3 radiation-hybrid
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Table 1
Mutations in Three FA-E Patients
Patient Ancestry Mutation Consequence for Protein
EUFA121 Turkey 355 CrT Q119X
EUFA410 Bangladesh 421 CrT R141X
EUFA622 Turkey IVS5-8GrAa R371_I372insLX
NOTE. Nucleotide numbering starts at the translation initiation
site. All these patients are homozygous for the indicated mutations.
a Mutation IVS5-8GrA (underlined) ttagctgtag ATC CTC creates
an alternative splice-acceptor site that results in false splicing and
insertion of six nucleotides from intron 5 (underlined), including an
in-frame stop codon GGA CGG ctg tag ATC CTC.
Figure 1 Complementation of MMC hypersensitivity in FA-E lymphoblastoid cell line EUFA410, and FANCE protein sequence. a,MMC
hypersensitivity of FA-E cell line EUFA410 is corrected after transfection of FANCE cDNA clone 10. HSC93, wild type control. b, Amino acid
sequence of the FANCE protein. Nuclear localization signals as predicted by PSORT II (Nakai and Horton, 1999) are shown in bold and
underlined.
panel was used to position FANCE betweenmicrosatellite
markers D6S439 and D6S1645, in agreement with the
genetic map location of FANCE (Waisfisz et al. 1999).
The FANCE cDNA appeared identical to a human ge-
nomic DNA sequence (clone 109F14 [Genbank accession
number AL022721]; Tripodis et al. 2000) on chromo-
some 6p21.2-21.3. A comparison between this genomic
DNA sequence and the FANCE cDNA revealed that the
FANCE gene has 10 exons spanning ∼15 kb of genomic
sequence. FANCE appears to be located between the
genes encoding the 60S ribosomal protein RPL10A (Csa-
19) and a ZNF127-like protein, a region in which cDNA
selection, exon trapping, and exon prediction programs
failed to detect a gene (Tripodis et al. 2000).
Mutation screening of the FANCE gene revealed a ho-
mozygous CrT transition in exon 2 of EUFA410, which
changes codon 141 into a stop codon (R141X; table 1).
The parents were heterozygous for this mutation. In the
FA-E reference cell line EUFA130 (Joenje et al. 1997), a
homozygous CrT nonsensemutationwas found in codon
119 (Q119X; table 1). The parents and unaffectedbrother
were heterozygous for this mutation. A homozygous mu-
tation IVS5-8GrA was detected in genomic DNA from
FA-E cell line EUFA622 (Waisfisz et al. 1999), which cre-
ates an alternative splice-acceptor site (table 1). Sequence
analysis of cDNA derived from EUFA622 indicated that
this mutation results in false splicing and incorporation
of six nucleotides from intron 5, including an in-frame
stop codon. These findings confirmed the identity of the
FANCE gene.
Our data show that FANCE encodes a novel protein
with two nuclear localization signals, which strongly sug-
gests that the pathway defective in FA patients has a nu-
clear function. Although recent evidence indicates that the
FA pathway might be involved in cellular detoxification
(Kruyt et al. 1998), transcriptional repression (Hoatlin et
al. 1999), or STAT1 activation (Pang et al. 2000), the
precise nature of this pathway remains to be elucidated.
Given that FANCE is localized in a region containing
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the HLA class I genes of the major histocompatibility
complex (Waisfisz et al. 1999; Tripodis et al. 2000), group
E patients are very unlikely to have an HLA-matched
unaffected sibling donor for successful bone marrow
transplantation. The cloning of FANCE now makes this
group of patients prime candidates for gene-therapy trials
aiming at genetic correction of their bone marrow failure
(Liu et al. 1999).
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